{"preliminary_commentary":{"by_channel":{"bluesky_thread":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"ERADICATE","nct_id":"NCT07198724","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=eradicate-nct07198724. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ERADICATE","arms":[{"description":"Up to 28 participants will be enrolled to determine the recommended phase 2 dosage of Elacestrant and will complete the following:\n\n* Baseline visit\n* Cycle 1 (21 day cycle)\n\n  * Days 1 through 21: Predetermined dose of Elacestrant 1x daily.\n  * Day 1: Predetermined dose of Trastuzumab Deruxtecan 1x daily.\n* Cycle 2 through End of Treatment (21 day cycle):\n\n  * Imaging every 9 weeks until Cycle 9, then every 12 weeks\n  * Day 1: tumor biopsy\n  * Days 1 through 21: Predetermined dose of Elacestrant 1x daily.\n  * Day 1: Predetermined dose of Trastuzumab Deruxtecan 1x daily.\n  * End of Treatment visit with imaging\n  * Follow up visits every 6 months\n  * If 3 or less out of 12 participants experience a dose-limiting toxicity (DLT), the recommended Phase II dose of Elacestrant will be that dose level. If there are 4 or more DLTs, Elacestrant dosage will de-escalate and 12 more participants will be enrolled.","label":"Phase 1b: Elacestrant + Trastuzumab Deruxtecan","type":"EXPERIMENTAL"},{"description":"37 participants will complete the following:\n\n* Baseline visit\n\n  -Cycle 1 (21 day cycle)\n* Days 1 through 21: Predetermined dose of Elacestrant 1x daily.\n* Day 1: Predetermined dose of Trastuzumab Deruxtecan 1x daily.\n\n  -Cycle 2 through End of Treatment (21 day cycle):\n* Imaging every 9 weeks until Cycle 9, then every 12 weeks\n* Day 1: tumor biopsy\n* Days 1 through 21: Predetermined dose of Elacestrant 1x daily.\n* Day 1: Predetermined dose of Trastuzumab Deruxtecan 1x daily.\n* End of Treatment visit with imaging\n* Follow up visits every 6 months","label":"Phase 2: Elacestrant + Trastuzumab Deruxtecan","type":"EXPERIMENTAL"}],"collaborators":["Stemline Therapeutics, Inc."],"completion_date":{"date":"2038-06-01","type":"ESTIMATED"},"conditions":["Metastatic Breast Cancer","HER2 Low Breast Carcinoma","HER2-negative Breast Cancer","Breast Cancer","Breast Cancer Female"],"enrollment":{"count":65,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Elacestrant","otherNames":["Elacestrant dihydrochloride","RAD1901"],"type":"DRUG"},{"name":"Trastuzumab Deruxtecan","otherNames":["Fam-Trastuzumab","ENHERTU","DS-8201a","T-DXd"],"type":"DRUG"}],"last_update":"2026-06-10","lead_sponsor":"Kristina A. Fanucci","official_title":"ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-06-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Recommended phase II dose (RP2D)","timeFrame":"Assessed at the end of the first treatment cycle, Day 21."},{"measure":"Objective Response Rate (ORR)","timeFrame":"assessed for response every 9 weeks (3 cycles) +/- 7 days for the first 27 weeks, then every 12 weeks +/- 7 days, and at end of treatment or start of new anticancer therapy, or up to approximately 24 months"}],"references":[],"start_date":{"date":"2025-11-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer","url":"https://clinicaltrials.gov/study/NCT07198724"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/eradicate-nct07198724"}